Evaxion Announces Business Update and Second Quarter 2023 Financial Results

[ad_1] Promising clinical data from Phase 1 and 2a studies with EVX-01 and EVX-02 were presented at AACR and ASCO in Q2 2023 A novel proprietary genetic vaccine adjuvant was…

Evaxion and Pennsylvania State University publish preclinical data validating our AI-based viral vaccine discovery platform

[ad_1] COPENHAGEN, Denmark, April 13, 2023 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in AI-powered immunotherapies, announces the successful publication in Frontiers of Immunology…

Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)

[ad_1] COPENHAGEN, Denmark, March 14, 2023 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today…